NFT
ALXO icon

Nan Fung Trinity’s ALX Oncology ALXO Stock Holding History

Nan Fung Trinity’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41,950
Closed -$47.4K – 64
2025
Q4 		$47.4K Hold
41,950
– – ﹤0.01% 78
2025
Q3 		$76.8K Hold
41,950
– – 0.01% 71
2025
Q2 		$17.4K Buy
+41,950
New +$21.2K ﹤0.01% 59

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Nan Fung Trinity's ALXO Position: Q1 2026 in Review

Nan Fung Trinity sold out of ALX Oncology (ALXO) in Q1 2026, closing a stake of 41,950 shares — an estimated $47.4K sold.

Nan Fung Trinity first reported a position in ALXO in Q2 2025 and held it in 3 quarters. The position peaked at $76.8K in Q3 2025. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Nan Fung Trinity reported no remaining ALX Oncology position as of Q1 2026 after selling out during the quarter.
  • Nan Fung Trinity sold 41,950 ALX Oncology shares in Q1 2026, an estimated $47.4K.
  • Nan Fung Trinity first reported a position in ALX Oncology in Q2 2025 and held it in 3 quarters.
  • Nan Fung Trinity's ALX Oncology position peaked at $76.8K in Q3 2025.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Nan Fung Trinity's 13F filing for Q1 2026, filed 5 May 2026.